Relay Therapeutics' zovegalisib meets efficacy endpoint in Phase 2 vascular anomalies trial

Relay Therapeutics reported that its PI3Kα inhibitor zovegalisib achieved the predefined efficacy threshold in a Phase 2 study of a rare genetic vascular anomaly. The data readout exceeded Wall Street expectations and suggests the drug may have utility beyond its original breast‑cancer focus.

The trial results were presented by CEO Sanjiv Patel, who highlighted the significance of the positive outcome for the company's broader research pipeline. The study adds a new indication to the portfolio of PI3Kα‑targeted therapies.

Analysts noted that the successful readout could improve the company's valuation and open opportunities for further development or partnership discussions.